Stemline Therapeutics prices $45 million public offering of common stock
Stemline Therapeutics announced pricing of an underwritten public offering of 4.5 million shares of its common stock at a price of $10.00 per share, with gross proceeds to Stemline of $45 million. Stemline has granted the underwriters a 30-day option to purchase up to 675,000 additional shares. January 20, 2017